Overview

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan